This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Peroxisome proliferator-activated receptor 3D structures
From Proteopedia
(Difference between revisions)
| Line 14: | Line 14: | ||
**[[2rew]] - hPPARα + azetidinone derivative activator<br /> | **[[2rew]] - hPPARα + azetidinone derivative activator<br /> | ||
**[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]], [[3vi8]], [[1i7g]], [[4bcr]], [[5hyk]] - hPPARα + agonist<br /> | **[[2znn]], [[2zno]], [[2znp]], [[2znq]], [[3kdu]], [[3vi8]], [[1i7g]], [[4bcr]], [[5hyk]] - hPPARα + agonist<br /> | ||
| - | **[[3fei]], [[3fej]], [[3g8i]], [[3sp6]] - hPPARα + agonist + NCOA1<br /> | + | **[[3fei]], [[3fej]], [[3g8i]], [[3sp6]], [[6l96]] - hPPARα + agonist + NCOA1 peptide<br /> |
| + | **[[3sp6]] - hPPARα + hPPARγ peptide + agonist<br /> | ||
| + | **[[6kxx]], [[6kxy]] - hPPARα + peptide + agonist<br /> | ||
**[[3et1]] - hPPARα + NCOA1 + indole derivative | **[[3et1]] - hPPARα + NCOA1 + indole derivative | ||
*'''PPARγ''';Ligand-binding domain 202-475 | *'''PPARγ''';Ligand-binding domain 202-475 | ||
| - | **[[3prg]], [[2qmv]], [[1prg]] – hPPARγ<br /> | + | **[[3prg]], [[2qmv]], [[1prg]], [[6l8b]] – hPPARγ<br /> |
**[[6fzy]], [[6fzg]] - hPPARγ (mutant) <br /> | **[[6fzy]], [[6fzg]] - hPPARγ (mutant) <br /> | ||
**[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]] – hPPARγ + ligand <br /> | **[[2zk0]], [[2zk1]], [[2zk2]], [[2zk3]], [[2zk4]], [[2zk5]], [[2zk6]], [[3vjh]], [[3vji]], [[4e4k]], [[4e4q]], [[4jl4]], [[5hzc]], [[4ci5]], [[4ci4]], [[6an1]], [[2f4b]], [[1zeo]], [[2ath]], [[2hwq]], [[2hwr]], [[2i4j]], [[2q59]], [[2q8s]], [[3b3k]], [[3bc5]], [[3cds]], [[3g9e]], [[3gbk]], [[3gz9]], [[3ia6]], [[3kdt]], [[3an3]], [[3an4]], [[3noa]], [[3r5n]], [[3r8a]], [[3vso]], [[3vsp]], [[2xkw]], [[3b0q]], [[3ho0]], [[3hod]], [[1knu]], [[1i7i]], [[1nyx]], [[2pob]], [[5azv]], [[6f2l]], [[6c5t]], [[6c5q]], [[5wr1]], [[5wr0]], [[5wqx]], [[6md2]], [[6md4]], [[6md1]], [[6md0]], [[6mcz]], [[6k0t]], [[6avi]], [[6aug]] – hPPARγ + ligand <br /> | ||
| Line 25: | Line 27: | ||
**[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | **[[3r8i]] - hPPARγ + ureidofibrate derivative<br /> | ||
**[[6o67]], [[6o68]], [[6dgr]], [[6dgq]], [[6dgo]], [[6dgl]], [[6d8x]], [[6c1i]] - hPPARγ + agonist<br /> | **[[6o67]], [[6o68]], [[6dgr]], [[6dgq]], [[6dgo]], [[6dgl]], [[6d8x]], [[6c1i]] - hPPARγ + agonist<br /> | ||
| - | **[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]], [[4em9]], [[4ema]], [[4prg]], [[2q6s]], [[5f9b]], [[4yt1]], [[3wmh]], [[6d3e]] - hPPARγ + partial agonist<br /> | + | **[[2g0h]], [[2g0g]], [[2i4p]], [[2i4z]], [[2q5g]], [[2q5p]], [[2q5s]], [[2q61]], [[2q6r]], [[3cdp]], [[3d6d]], [[4em9]], [[4ema]], [[4prg]], [[2q6s]], [[5f9b]], [[4yt1]], [[3wmh]], [[6d3e]], [[6l89]] - hPPARγ + partial agonist<br /> |
**[[2om9]] - hPPARγ + cannabinoid<br /> | **[[2om9]] - hPPARγ + cannabinoid<br /> | ||
**[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | **[[3b0r]], [[5lsg]], [[4r6s]], [[4r2u]], [[4r06]], [[6dh9]], [[6dcu]], [[6dbh]] - hPPARγ + antagonist<br /> | ||
| Line 32: | Line 34: | ||
**[[2zvt]] - hPPARγ (mutant) + modulator<br /> | **[[2zvt]] - hPPARγ (mutant) + modulator<br /> | ||
**[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | **[[2vsr]], [[2vst]], [[2vv0]], [[2vv1]], [[2vv2]], [[2vv3]], [[2vv4]], [[3x1i]], [[3x1h]], [[3wj5]], [[3wj4]], [[3po9]], [[3sz1]] - hPPARγ + fatty acid activator<br /> | ||
| - | **[[3ads]], [[3adx]], [[5u5l]], [[4xum]], [[4xuh]], [[4xta]], [[4xld]], [[6d5a]] - hPPARγ + anti-inflammatory drug<br /> | + | **[[6jey]] - hPPARγ + fatty acid<br /> |
| + | **[[6jf0]] - hPPARγ + fluorescent probe<br /> | ||
| + | **[[6mcz]], [[6md0]], [[6md1]], [[6md2]], [[6qj5]], [[6t9c]] - hPPARγ + ligand<br /> | ||
| + | **[[6tsg]] - hPPARγ + hormone<br /> | ||
| + | **[[3ads]], [[3adx]], [[5u5l]], [[4xum]], [[4xuh]], [[4xta]], [[4xld]], [[6d5a]], [[6o67]], [[6o68]] - hPPARγ + anti-inflammatory drug<br /> | ||
**[[4oj4]] - hPPARγ (mutant) + anti-inflammatory drug<br /> | **[[4oj4]] - hPPARγ (mutant) + anti-inflammatory drug<br /> | ||
**[[3adv]] - hPPARγ + serotonin<br /> | **[[3adv]] - hPPARγ + serotonin<br /> | ||
**[[3k8s]], [[3et0]], [[2yfe]], [[4a4v]], [[4a4w]], [[4jaz]], [[5tto]], [[4pwl]], [[4pvu]], [[5y2t]], [[5y2o]], [[5ugm]], [[6dha]] - hPPARγ + antidiabetic drug<br /> | **[[3k8s]], [[3et0]], [[2yfe]], [[4a4v]], [[4a4w]], [[4jaz]], [[5tto]], [[4pwl]], [[4pvu]], [[5y2t]], [[5y2o]], [[5ugm]], [[6dha]] - hPPARγ + antidiabetic drug<br /> | ||
**[[4o8f]] - hPPARγ (mutant) + antidiabetic drug<br /> | **[[4o8f]] - hPPARγ (mutant) + antidiabetic drug<br /> | ||
| + | **[[6md4]] - hPPARγ + oleic acid + antidiabetic drug<br /> | ||
**[[6enq]] - hPPARγ + antifibrotic drug<br /> | **[[6enq]] - hPPARγ + antifibrotic drug<br /> | ||
| Line 44: | Line 51: | ||
**[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCOA2 peptide + inhibitor<br /> | **[[5dwl]], [[5dvc]], [[5dv8]], [[5dv6]], [[5dv3]], [[5dsh]] - hPPARγ + NCOA2 peptide + inhibitor<br /> | ||
**[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | **[[1zgy]] – hPPARγ + antidiabetic drug + nuclear receptor peptide<br /> | ||
| - | **[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[6jq7]], [[6izm]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[5ycp]], [[5ycn]] - hPPARγ + NCOA1 peptide<br /> | + | **[[2gtk]], [[3qt0]], [[5gtp]], [[5gto]], [[5gtn]], [[6jq7]], [[6izm]], [[6ilq]], [[6ijs]], [[6ijr]], [[6icj]], [[5ycp]], [[5ycn]], [[6ktm]], [[6ktn]] - hPPARγ + NCOA1 peptide<br /> |
**[[3cs8]], [[3u9q]]- hPPARγ + PGC-1A peptide<br /> | **[[3cs8]], [[3u9q]]- hPPARγ + PGC-1A peptide<br /> | ||
**[[3cwd]] - hPPARγ + NCOA1-2 peptide<br /> | **[[3cwd]] - hPPARγ + NCOA1-2 peptide<br /> | ||
| - | **[[5two]], [[6izn]], [[6fzp]], [[6fzj]], [[6fzf]] - hPPARγ + modulating ligand<br /> | + | **[[5two]], [[6izn]], [[6fzp]], [[6fzj]], [[6fzf]], [[6t6b]] - hPPARγ + modulating ligand<br /> |
**[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]] - hPPARγ + SRC-1 peptide + modulator<br /> | **[[3fur]], [[3kmg]], [[3v9t]], [[3v9v]], [[3v9y]], [[4f9m]], [[3b1m]], [[3lmp]] - hPPARγ + SRC-1 peptide + modulator<br /> | ||
| - | **[[4fgy]], [[2prg]] - hPPARγ + antidiabetic | + | **[[4fgy]], [[2prg]] - hPPARγ + antidiabetic drug + NCOA1 peptide<br /> |
| + | **[[6oni]], [[6pdz]] - hPPARγ + agonist + NCOR peptide<br /> | ||
**[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | **[[6ad9]] - hPPARγ + anticancer agent + NCOA1 peptide<br /> | ||
**[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | **[[3s9s]], [[3t03]], [[2fvj]]- hPPARγ + NCOA1 peptide + partial agonist<br /> | ||
| Line 62: | Line 70: | ||
**[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | **[[6dgp]], [[5z6s]], [[5z5s]] - hPPARγ + coactivator peptide<br /> | ||
**[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | **[[6d94]] - hPPARγ + mediator of RNA polymerase II peptide<br /> | ||
| + | **[[6onj]] - hPPARγ + mediator of RNA polymerase II peptide + antidiabetic drug<br /> | ||
*'''PPARδ''';Ligand-binding domain 171-441 | *'''PPARδ''';Ligand-binding domain 171-441 | ||
Revision as of 09:59, 21 September 2020
3D Structures of PPAR
Updated on 21-September-2020
